title: Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
authors.affiliation: Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
authors.forename: M M
authors.initials: MM
authors.lastname: van den Heuvel-Eibrink
authors.affiliation: Paediatric Oncology, University College London Institute of Child Health, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Pritchard-Jones
authors.affiliation: Dept. of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: van Tinteren
authors.affiliation: Department of Paediatric Oncology, University Hospital Homburg/Saar, Homburg, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Graf
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use; D009396:Wilms Tumor / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D003609:Dactinomycin; D014750:Vincristine